Measles Cases Rise to 8,889 Across Mexico

Mexico has confirmed 28 measles-related deaths and 8,889 cases across all 32 states, prompting intensified vaccination and surveillance measures by federal authorities. The resurgence increases operational and compliance pressure on the healthcare system, pharmaceutical suppliers, private providers and employers, while raising regulatory scrutiny around immunization coverage and public health coordination. Sustaining elimination status and avoiding broader economic disruption will require vaccination rates above 95%, reinforcing implications for healthcare investment, supply chains and workforce continuity in Mexico.

Mexico has confirmed 28 measles-related deaths and nearly 9,000 cases nationwide as transmission continues across all 32 states. Federal authorities, local governments and academic institutions are intensifying vaccination and surveillance to contain the outbreak. The response is unfolding alongside broader efforts to strengthen domestic vaccine production and supply chain oversight.

“The state of measles in Mexico is dynamic and requires attention and collective responsibility,” reported the Gaceta UNAM, citing increased virus circulation, rising case counts and recent fatalities. Federal health officials have similarly emphasized vaccination as the primary tool to interrupt transmission.

Transmission Extends Beyond Initial Epicenter

According to the Ministry of Health, measles transmission remains active in 319 municipalities across the country. The General Directorate of Epidemiology has confirmed 8,889 cases nationwide, while a separate cumulative report placed total confirmed infections at 9,074 between Jan. 1, 2025, and Feb. 10, 2026.

On Feb. 10, authorities reported an additional fatality linked to a 2025 infection in Mexico City, bringing total confirmed deaths to 28. Of those, 21 occurred in Chihuahua, two in Jalisco and one each in Sonora, Durango, Mexico City, Michoacan and Tlaxcala. Most deaths were recorded in 2025, though Michoacan and Tlaxcala registered fatalities in 2026.

The outbreak began in Chihuahua in February 2025, where 4,493 to 4,505 cases were recorded over the 2025–2026 period. While case counts in that state have declined sharply in early 2026, infections have expanded to other regions. So far this year, Jalisco leads in confirmed cases, followed by Chiapas, Sinaloa and Mexico City.

Epidemiological data indicate that infants under one year have the highest incidence rate, followed by children ages one to four and five to nine. Adults ages 20 to 40 represent a significant share of infections, reflecting gaps in booster coverage. Gaceta UNAM reports that most confirmed cases involve individuals who are unvaccinated or whose immunization schedules are incomplete.

Nationally, the case fatality rate remains below 0.5%, according to federal data. Health officials note that confirmation of cases and deaths may take weeks due to laboratory analysis and epidemiological review.

Regional Alert and Coverage Gaps

The resurgence in Mexico forms part of a broader regional trend. In Nov. 2025, the Pan American Health Organization (PAHO) confirmed that the Americas no longer met the criteria for measles elimination after sustained transmission in several countries.

In 2025, countries in the region reported 14,891 confirmed cases and 29 deaths, a 32-fold increase compared with 466 cases in 2024. Mexico accounted for 6,428 cases and 24 deaths in 2025, while Canada and the United States also recorded outbreaks. During the first three weeks of 2026, Mexico confirmed 740 additional cases, contributing to a 43-fold increase compared with the same period a year earlier.

Regional first-dose measles vaccination coverage reached 88% in 2024, with second-dose coverage at 79%, both below the 95% threshold required to prevent outbreaks. Approximately 1.5 million children in the Americas did not receive any measles vaccine dose in 2024. Among confirmed cases with known vaccination status, 78% were unvaccinated.

“Measles is the world’s most contagious virus,” said Tedros Adhanom Ghebreyesus, noting that immunity gaps can reverse prior gains. The Americas had reduced cases from more than 116,000 in 2019 to 2,320 in 2024, achieving re-verification of elimination before the recent setback.

With the 2026 FIFA World Cup expected to bring more than 5.5 million international visitors to Mexico, authorities are coordinating with PAHO and international partners to strengthen surveillance and outbreak response during periods of increased mobility.

Vaccination Expansion and Manufacturing Strategy

Mexico’s Ministry of Health says it has sufficient vaccine supply for the next two years and has requested a short extension from PAHO’s Regional Monitoring and Re-Verification Commission ahead of its April 13, 2026, review of elimination status.

Authorities report that 23.5 million doses of measles-mumps-rubella and measles-rubella vaccines have been deployed nationwide, with more than 11.8 million administered since the outbreak began. Campaigns include routine two-dose schedules for children, a “dose zero” for infants ages six to 11 months and catch-up immunization for adolescents and adults up to 49 years old.

More than 21,000 vaccination points operate nationwide, and approximately 28 million doses are available. Strategies include house-to-house visits, mobile brigades and vaccination perimeters covering 25 city blocks around confirmed cases. In Mexico City, authorities have installed vaccination modules in subway stations and other high-traffic locations.

University institutions have reinforced prevention guidance. The National Autonomous University of Mexico (UNAM) advised its community to verify vaccination records, use face masks in enclosed spaces when appropriate, improve ventilation and report suspected cases. The guidance states that activities should not be automatically suspended if cases appear but that preventive measures should be intensified.

Parallel to outbreak control, Mexico is expanding domestic vaccine manufacturing capacity. President Claudia Sheinbaum recently announced a five-year agreement with Moderna, BIRMEX and Laboratorios Liomont to produce messenger RNA vaccines locally. The plan includes phased technology transfer, beginning with fill-and-finish operations and progressing toward full domestic manufacturing.

Health officials say the partnership is designed to secure long-term supply and reduce dependence on external production during global health emergencies. The strategy extends beyond COVID-19 to potential vaccines targeting dengue and certain cancers.

At the global level, the World Health Organization recently prequalified an additional novel oral polio vaccine type 2, expanding global supply and reinforcing diversified manufacturing. Mexican authorities cite such developments as evidence of the need for resilient procurement channels and strengthened supply oversight.

Mexico has also launched a national monitoring platform to track compliance in the delivery of health supplies across major public institutions. Officials say the system will improve fulfillment rates, reduce bottlenecks and enhance transparency in procurement.

Public health experts state that restoring measles elimination status will require sustained coverage above 95% with two doses, continued surveillance and coordinated political commitment. While current case numbers remain manageable relative to population size, authorities emphasize that measles can spread rapidly in under-immunized communities.